Keros Therapeutics (NASDAQ:KROS) Cut to Strong Sell at Wall Street Zen

Posted by Brian Himes on Nov 4th, 2026

Wall Street Zen lowered shares of Keros Therapeutics (NASDAQ:KROS – Free Report) from a sell rating to a strong sell rating in a research note issued to investors on Sunday,Wall Street Zen reports.

Several other research analysts also recently commented on KROS. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. Leerink Partners dropped their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Finally, Wells Fargo & Company decreased their target price on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $20.50.

View Our Latest Research Report on Keros Therapeutics

Keros Therapeutics Stock Up 0.7%

KROS opened at $10.83 on Friday. Keros Therapeutics has a twelve month low of $9.69 and a twelve month high of $22.55. The firm’s 50-day simple moving average is $11.27 and its 200-day simple moving average is $12.06.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Equities analysts expect that Keros Therapeutics will post -5.27 earnings per share for the current fiscal year.

Keros Therapeutics declared that its Board of Directors has authorized a share buyback program on Wednesday, September 9th that authorizes the company to repurchase $5 million in shares. This repurchase authorization authorizes the company to reacquire up to 2.3% of its shares through open market purchases. Share repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Insider Activity

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the sale, the insider directly owned 27,559 shares of the company’s stock, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 5,343 shares of company stock worth $54,985 in the last quarter. 12.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in Keros Therapeutics in the 2nd quarter valued at $90,000. PDT Partners LLC bought a new stake in shares of Keros Therapeutics during the second quarter worth $122,000. Lazard Asset Management LLC bought a new stake in shares of Keros Therapeutics during the first quarter worth $129,000. Canada Pension Plan Investment Board acquired a new position in shares of Keros Therapeutics during the second quarter valued at $247,000. Finally, Quantinno Capital Management LP lifted its stake in shares of Keros Therapeutics by 12.5% during the first quarter. Quantinno Capital Management LP now owns 23,759 shares of the company’s stock valued at $262,000 after acquiring an additional 2,639 shares during the period. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.